North East and North Cumbria
ICS Formulary
ICS Formulary
1 Gastro-intestinal system
01-04-02 Antimotility drugs
| Loperamide |
|
First Choice
|
|
 MHRA Drug Safety Alert Sept 2017: Loperamide (Imodium): Reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse |
|
| Teduglutide Revestive® |
|
Formulary
|
|
|
NICE TA804: Teduglutide for treating short bowel syndrome |
|
Links
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities- MHRA Drug Safety Alert Sept 2017: Loperamide (Imodium): Reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse
- MHRA Drug Safety Update (Dec 2014): Codeine for analgesia: restricted use in children because of reports of morphine toxicity
- MHRA Drug Safety Update (Dec 2014): Codeine: very rare risk of side-effects in breastfed babies
- NICE CG84: Diarrhoea and vomiting in children under 5
- NICE TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea
- NICE TA804: Teduglutide for treating short bowel syndrome
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence